[go: up one dir, main page]

WO2003048359A1 - Marqueurs des troubles du metabolisme des sucres et des lipides et leur utilisation - Google Patents

Marqueurs des troubles du metabolisme des sucres et des lipides et leur utilisation Download PDF

Info

Publication number
WO2003048359A1
WO2003048359A1 PCT/JP2002/012793 JP0212793W WO03048359A1 WO 2003048359 A1 WO2003048359 A1 WO 2003048359A1 JP 0212793 W JP0212793 W JP 0212793W WO 03048359 A1 WO03048359 A1 WO 03048359A1
Authority
WO
WIPO (PCT)
Prior art keywords
sugar
metabolic disorders
lipid metabolic
markers
utilization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/012793
Other languages
English (en)
Japanese (ja)
Inventor
Junji Ichihara
Eiji Sugaru
Mutsuo Taiji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Priority to AU2002361078A priority Critical patent/AU2002361078A1/en
Publication of WO2003048359A1 publication Critical patent/WO2003048359A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11025—Mitogen-activated protein kinase kinase kinase (2.7.11.25), i.e. MAPKKK or MAP3K
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention porte sur des polynucléotides présentant au moins 15 bases consécutives de la séquence de bases du gène MLTK et/ou sur les polynucléotides complémentaires de ces polynucléotides, et servant de marqueurs des troubles du métabolisme des sucres et des lipides, sur un procédé de détection desdits troubles à l'aide desdits marqueurs, et sur un procédé de criblage de médicaments utiles pour améliorer lesdits troubles.
PCT/JP2002/012793 2001-12-05 2002-12-05 Marqueurs des troubles du metabolisme des sucres et des lipides et leur utilisation Ceased WO2003048359A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002361078A AU2002361078A1 (en) 2001-12-05 2002-12-05 Markers for sugar/lipid metabolic disorders and utilization thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-371420 2001-12-05
JP2001371420 2001-12-05
JP2002-41542 2002-02-19
JP2002041542A JP2003230388A (ja) 2001-12-05 2002-02-19 糖・脂質代謝異常疾患マーカーおよびその利用

Publications (1)

Publication Number Publication Date
WO2003048359A1 true WO2003048359A1 (fr) 2003-06-12

Family

ID=26624888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/012793 Ceased WO2003048359A1 (fr) 2001-12-05 2002-12-05 Marqueurs des troubles du metabolisme des sucres et des lipides et leur utilisation

Country Status (3)

Country Link
JP (1) JP2003230388A (fr)
AU (1) AU2002361078A1 (fr)
WO (1) WO2003048359A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118833A3 (fr) * 2004-06-01 2006-05-11 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour des maladies associees a une kinase a motif sterile-alpha et a motif de type glissiere a leucine (zak)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021792A1 (fr) * 2003-08-28 2005-03-10 Dainippon Sumitomo Pharma Co., Ltd. Produit prophylactique ou remede contre la maladie intestinale inflammatoire, contenant un anticorps anti-cd81 comme principe actif

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0735370A1 (fr) * 1995-03-28 1996-10-02 Takeda Chemical Industries, Ltd. Méthode d'essai de MAP-kinase
WO1998053050A2 (fr) * 1997-05-21 1998-11-26 The Children's Medical Center Corporation Peptides courts modulant selectivement l'activite de serine/threonine kinases
WO2000014212A1 (fr) * 1998-09-09 2000-03-16 Millennium Pharmaceuticals, Inc. Nouvelles molecules de proteine kinase et leurs utilisations
WO2001012670A1 (fr) * 1999-08-13 2001-02-22 Human Genome Sciences, Inc. Polynucleotides, polypeptides du recepteur du tgf-beta et anticorps

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0735370A1 (fr) * 1995-03-28 1996-10-02 Takeda Chemical Industries, Ltd. Méthode d'essai de MAP-kinase
WO1998053050A2 (fr) * 1997-05-21 1998-11-26 The Children's Medical Center Corporation Peptides courts modulant selectivement l'activite de serine/threonine kinases
WO2000014212A1 (fr) * 1998-09-09 2000-03-16 Millennium Pharmaceuticals, Inc. Nouvelles molecules de proteine kinase et leurs utilisations
WO2001012670A1 (fr) * 1999-08-13 2001-02-22 Human Genome Sciences, Inc. Polynucleotides, polypeptides du recepteur du tgf-beta et anticorps

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ISAMU GOTOH ET AL.: "Identification and characterization of a novel MAP kinase kinase kinase, MLTK", THE JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, pages 4276 - 4286, XP002965828 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118833A3 (fr) * 2004-06-01 2006-05-11 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour des maladies associees a une kinase a motif sterile-alpha et a motif de type glissiere a leucine (zak)

Also Published As

Publication number Publication date
JP2003230388A (ja) 2003-08-19
AU2002361078A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
USD489717S1 (en) Tablet personal computer
USD482368S1 (en) Display for touchscreen of a computer monitor
USD469091S1 (en) Computer display
USD488807S1 (en) Computer
USD480079S1 (en) Notebook computer
EP2821085A3 (fr) Interférence ARN pour le traitement de troubles à gain
AU2003301957A1 (en) Administration of anti-inflammatory drugs into the central nervous system
USRE40391E1 (en) Computer
USD491075S1 (en) Clock
USD499812S1 (en) Pregnancy testing stick
WO2002072604A3 (fr) Genes et polymorphismes associes a une maladie cardiovasculaire et leur utilisation
USD490415S1 (en) Thin personal computer
AU2002336759A1 (en) Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism
USD495709S1 (en) Display monitor
AU2002319717A1 (en) Mutant nurr1 gene in parkinson's disease
USD517613S1 (en) Playing card
WO2003057874A1 (fr) Marqueurs de maladies pour maladies renales et leur utilisation
USD454931S1 (en) Computer for an exercise device
USD494671S1 (en) Nose clip
WO2003022993A3 (fr) Procedes relatifs a l'elaboration de modeles ex vivo pour maladies inflammatoires, et utilisations correspondantes
WO2003048359A1 (fr) Marqueurs des troubles du metabolisme des sucres et des lipides et leur utilisation
USD518386S1 (en) Clock
USD513241S1 (en) LCD television
USD491073S1 (en) Clock
USD502886S1 (en) Precious stone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase